Gallium-68 labelled RGD peptides evaluation for imaging of glioblastoma multiforme
The thesis is focused into critical evaluation of three different RGD peptides coupled with chelators to enable their radiolabelling with gallium-68. RGD peptides are accumulated in tumors expressing αvβ3 integrin (marker of angiogenesis). Such radiolabelled RGD peptides could be succesfully used to image tumors in vivo. Our study will include all appropriate stages of radiopharmaceutical testing i.e. optimalisation of lablelling conditions, radiochemical purity tests (HPLC, TLC), plasma stability assays, testing of stability in various chemical enviroments, octanol-water partition coefficient determination. Suitable derivatives will be passed to in vitro tests employing cell line U-87 MG (glioblastoma multiforme) to assess their ability to bind to tumor cells. Finally the appropriate candidates will be used for in vivo imaging of gliomas in mouse model. The imaging will be carried out in microPET/CT system and its results will be compared with ex vivo biodistribution study.